The incorporation of immune checkpoint blockade into the treatment paradigm for ALK/EGFR-negative surgically resectable early-stage NSCLC was a tremendous advance in therapy and patient outcomes. The gene discussed is ALK; the disease is non-small cell lung carcinoma.